FDA Changes Course, Advises Updated COVID-19 Vaccines Target KP.2 Strain

The U.S. Food and Drug Administration (FDA) on June 13 changed course and recommended COVID-19 manufacturers target the KP.2 virus strain in their next round of shots.

The regulatory agency had said earlier this month it was following advice from its advisers and directing manufacturers to target the JN.1 variant.

The change “is intended to ensure that the COVID-19 vaccines (2024-2025 Formula) more closely match circulating SARS-CoV-2 strains,” the regulators said. SARS-CoV-2 is the virus that causes COVID-19.

The change is “based on the most current available data, along with the recent rise in cases of COVID-19 in areas of the country,” the FDA said in a statement.

The regulators, though, said manufacturers could choose whether or not to target KP.2, a sublineage of JN.1.

Read Full Article Here